[New aspects of therapy with oral antidiabetic agents].
D000138:Acidosis / Q000139:chemically induced; D001645:Biguanides / Q000627:therapeutic use; D001798:Blood Proteins / Q000378:metabolism; D002747:Chlorpropamide / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000188:drug therapy*; D003928:Diabetic Nephropathies / Q000378:metabolism; D004347:Drug Interactions; D005905:Glyburide / Q000627:therapeutic use; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000378:metabolism / Q000627:therapeutic use*; D011485:Protein Binding; D013449:Sulfonamides / Q000627:therapeutic use; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D014044:Tolbutamide / Q000378:metabolism / Q000627:therapeutic use
D001645:Biguanides; D001798:Blood Proteins; D007004:Hypoglycemic Agents; D013449:Sulfonamides; D013453:Sulfonylurea Compounds; D014044:Tolbutamide; D005905:Glyburide; D002747:Chlorpropamide
Neuere Gesichtspunkte der Therapie mit oralen Antidiabetika.